Jain, Tania <br/><br/>
Single dose versus multiple doses of rituximab for preemptive therapy of Epstein-Barr virus reactivation after hematopoietic cell transplantation.  [electronic resource] 

 -  Leukemia & lymphoma  01 2019 
 - 110-117 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article 
<br/><br/><label>ISSN: </label>1029-2403 
<br/><br/><label>Standard No.: </label>10.1080/10428194.2018.1459603  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Clinical Decision-Making--methods<br/>Drug Administration Schedule<br/>Epstein-Barr Virus Infections--epidemiology<br/>Female<br/>Follow-Up Studies<br/>Hematopoietic Stem Cell Transplantation--adverse effects<br/>Herpesvirus 4, Human--drug effects<br/>Humans<br/>Lymphoproliferative Disorders--mortality<br/>Male<br/>Middle Aged<br/>Models, Biological<br/>Patient Selection<br/>Retrospective Studies<br/>Risk Factors<br/>Rituximab--administration & dosage<br/>Survival Analysis<br/>Transplantation, Homologous--adverse effects<br/>Treatment Outcome<br/>Viral Load--drug effects<br/>Viremia--epidemiology<br/>Virus Activation--drug effects<br/>Young Adult